Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | PIK3CA |
| Variant | E542V |
| Impact List | missense |
| Protein Effect | gain of function |
| Gene Variant Descriptions | PIK3CA E542V is a hotspot mutation that lies within the PIK helical domain of the Pik3ca protein (UniProt.org). E542V confers a gain of function on Pik3ca, as indicated by increased phosphorylation of Akt and Mek1/2, growth-factor independent cell survival, and is transforming in culture (PMID: 26627007, PMID: 29533785). |
| Associated Drug Resistance | |
| Category Variants Paths |
PIK3CA mutant PIK3CA act mut PIK3CA E542V PIK3CA mutant PIK3CA exon10 PIK3CA E542X PIK3CA E542V |
| Transcript | NM_006218.4 |
| gDNA | chr3:g.179218295A>T |
| cDNA | c.1625A>T |
| Protein | p.E542V |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| XM_006713658 | chr3:g.179218295A>T | c.1625A>T | p.E542V | RefSeq | GRCh38/hg38 |
| XM_006713658.5 | chr3:g.179218295A>T | c.1625A>T | p.E542V | RefSeq | GRCh38/hg38 |
| NM_006218.4 | chr3:g.179218295A>T | c.1625A>T | p.E542V | RefSeq | GRCh38/hg38 |
| NM_006218 | chr3:g.179218295A>T | c.1625A>T | p.E542V | RefSeq | GRCh38/hg38 |
| XM_011512894.2 | chr3:g.179218295A>T | c.1625A>T | p.E542V | RefSeq | GRCh38/hg38 |
| XM_011512894 | chr3:g.179218295A>T | c.1625A>T | p.E542V | RefSeq | GRCh38/hg38 |
| XM_006713658.4 | chr3:g.179218295A>T | c.1625A>T | p.E542V | RefSeq | GRCh38/hg38 |
| NM_006218.3 | chr3:g.179218295A>T | c.1625A>T | p.E542V | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PIK3CA E542V | colorectal cancer | predicted - sensitive | Cetuximab | Case Reports/Case Series | Actionable | In a retrospective analysis, Erbitux (cetuximab) treatment resulted in stable disease in a colorectal carcinoma patient harboring a PIK3CA E542V mutation (PMID: 25714871). | 25714871 |